Page 1

А VTV THERAPEUTICS Exhibit 99.1 vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Phase 3 CATTI trial evaluating cadisegliatin for the treatment of type 1 diabetes ( TID ) expected to complete enrollment in third of 2026 Cadisegliatin Phase 2a hybrid closed - loop trial ( Hybrid CATTI ) in T1D to initiate before year end 2026 quarter Strong balance sheet expected to fund operations through anticipated CATTI topline data readout Company to host Key Opinion Leader ( KOL ) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with TID HIGH POINT , N.C. , August 6 , 2026 ( GLOBE NEWSWIRE ) – vTv Therapeutics Inc. ( Nasdaq : VTVT ) , a late - stage biopharmaceutical company advancing cadisegliatin , a novel oral investigational therapy for type 1 diabetes ( T1D ) , today reported financial results for the second quarter ended June 30 , 2026 , and provided a corporate update . The Company expects to complete enrollment in the Phase 3 CATT1 trial in the third quarter of 2026. Based on its current cash position at the end of the second quarter of 2026 , vTv expects to have sufficient cash to fund operations through the anticipated CATT1 topline data readout . In the fourth quarter of 2026 , the Company also plans to host a Key Opinion Leader ( KOL ) event focused on T1D , the burden of managing hypoglycemia without compromising glycemic control , and cadisegliatin's potential to address this significant unmet need . " Cadisegliatin has been specifically designed to address the significant unmet need of hypoglycemia , a major limiting factor in achieving optimal blood glucose control in T1D , " said Paul Sekhri , Chairman , President , and CEO of vTv Therapeutics . " We look forward to discussing cadisegliatin's potential with leading experts in T1D at our planned fourth - quarter KOL event . With cash runway through our anticipated topline data readout , we are focused on advancing development of the potential first oral adjunctive therapy for people with T1D . " Recent Company Highlights • • CATT1 Trial Advancing . Enrollment in the ongoing Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in individuals with T1D is expected to be completed in the third quarter of 2026 . KOL Event on Cadisegliatin Program . In the fourth quarter of 2026 , the Company plans to host a KOL event focused on T1D , the significant unmet medical need of hypoglycemia , and the cadisegliatin Phase 3 clinical program . Cadisegliatin Hybrid Closed - Loop Trial ( Hybrid CATT1 ) . vTv expects to initiate the Phase 2a Hybrid CATT1 trial before year end 2026. This randomized , double - blind , crossover , multicenter study will evaluate cadisegliatin in T1D participants using hybrid closed - loop insulin delivery systems to inform the design and operational aspects of future Phase 3 research in this population .